Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Kyowa Hakko announces agreement for antibody licence

Kyowa Hakko announces agreement for antibody licence

6th March 2008

Kyowa Hakko has announced its entrance into an agreement which will see Amgen exclusively develop and commercialise a humanised monoclonal antibody.

The deal will see Amgen receive the exclusive licence for KW-0761 and take on global responsibilities, with the exception of Taiwan, China, Korea and Japan, where Kyowa Hakko will retain rights.

Terms of the agreement include a $100 million (50.12 million pounds) payment from Amgen, although Kyowa Hakko could receive a maximum of $420 million in other payments for development, sales and approval targets.

KW-0761 has so far been studied at phase I stage by Kyowa Hakko in the areas of inflammation and oncology.

Meanwhile, Amgen has recently released information regarding trials of one of its offerings, Vectibix.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.